---
id: esmo-cll-2025
title: "ESMO Clinical Practice Guideline: Chronic Lymphocytic Leukemia (2025 Update)"
short_title: "ESMO CLL 2025"

organization: European Society for Medical Oncology
collaborators: null
country: Global (Europe-led)
url: https://www.esmo.org/guidelines/guidelines-by-topic/haematological-malignancies/chronic-lymphocytic-leukaemia
doi: null
pmid: null
open_access: true

specialty: oncology
guideline_type: clinical-practice
evidence_system: ESMO
conditions:
  - chronic lymphocytic leukemia
  - CLL
  - small lymphocytic lymphoma
  - SLL
tags:
  - BTK inhibitors
  - BCL2 inhibitors
  - venetoclax
  - MRD
  - immunotherapy

publication_date: 2025-03-20
previous_version_date: 2020-09-01
status: current
supersedes: null
superseded_by: null

pdf_path: null
has_pdf: false
last_reviewed: 2025-12-23
---

## Scope
Updated evidence-based recommendations from ESMO for the management of patients with Chronic Lymphocytic Leukemia (CLL), incorporating new data on targeted therapies and the role of measurable residual disease (MRD).

## Key Recommendations

### Diagnosis and Prognostication
- **Diagnosis**: Requires a peripheral blood lymphocytosis â‰¥5 x 10^9/L with a characteristic immunophenotype (CD5+, CD19+, CD23+, weak sIg, CD20 low).
- **TP53 and IGHV**: Mandatory testing for TP53 mutation/deletion and IGHV mutational status prior to starting frontline therapy.

### Frontline Therapy
- **Fit Patients (Regardless of IGHV)**: Preferred options include:
    - **BTK Inhibitors** (e.g., Acalabrutinib, Zanubrutinib) continuous therapy.
    - **Venetoclax + Obinutuzumab** fixed-duration therapy (1 year).
- **TP53 Disruption**: Continuous BTK inhibitors are the preferred strategy for patients with TP53 mutation or del(17p).

### Role of Measurable Residual Disease (MRD)
- **New Standard**: Recommends the use of MRD (threshold <10^-4) as a secondary endpoint to guide the duration of treatment in clinical trials and increasingly in routine practice (specifically for Venetoclax-based combinations).

### Management of Relapsed/Refractory Disease
- **Class Switching**: If a patient relapses on a BTK inhibitor, switching to a Venetoclax-based regimen is recommended, and vice-versa.
- **Pirtobrutinib**: Recommended as a preferred option for patients who have failed both covalent BTK inhibitors and BCL2 inhibitors.

### Supportive Care
- **Infection Prophylaxis**: High risk of opportunistic infections; recommends monitoring for HBV reactivation and considering prophylaxis for PJP/VZV during intensive therapy.
- **Vaccination**: Annual influenza and up-to-date COVID-19/Pneumococcal vaccination are strongly recommended, ideally before starting treatment.

### Richter Transformation
- **Biopsy**: Mandatory lymph node biopsy if Richter transformation is suspected (e.g., rapid lymph node growth, B-symptoms, rising LDH).
- **Management**: Aggressive chemo-immunotherapy followed by stem cell transplantation in eligible patients remains the standard.
